Dengue fever: Causes, complications, and vaccine strategies – A review

S Oviya; S Kaviya; S Udhaya

doi:10.30574/gscbps.2019.6.3.0024

Authors

S Oviya Department of Microbiology, Annamalai University, Chidambaram, India.
S Kaviya Department of Microbiology, Annamalai University, Chidambaram, India.
S Udhaya Department of Microbiology, Annamalai University, Chidambaram, India.

DOI:

https://doi.org/10.30574/gscbps.2019.6.3.0024

Keywords:

Dengue, Dengue causes, Complications, Vaccine

Abstract

Dengue is an extremely endemic infectious disease of the tropical countries and is rapidly becoming a global burden. It is caused by any of the four serotypes of dengue virus and is transmitted within humans through female Aedes mosquitoes. Dengue disease varies from mild fever to severe conditions of dengue hemorrhagic fever and shock syndrome. Globalization, increased air travel, and unplanned urbanization have led to increase in the rate of infection and helped dengue to expand its geographic and demographic distribution. Dengue vaccine development has been a challenging task due to the existence of four antigenically distinct dengue virus serotypes, each capable of eliciting cross-reactive and disease-enhancing antibody response against the remaining three serotypes. Recently, Sanofi Pasteur’s chimeric live-attenuated dengue vaccine candidate has been approved in Mexico, Brazil, and Philippines for usage in adults between 9 and 45 years of age. The impact of its limited application to the public health system needs to be evaluated. Simultaneously, the restricted application of this vaccine candidate warrants continued efforts in developing a dengue vaccine candidate which is additionally efficacious for infants and native individuals. In this context, alternative strategies of developing a designed vaccine candidate which does not allow production of enhancing antibodies should be explored, as it may expand the umbrella of efficacy to include infants and native individuals.

Metrics

Metrics Loading ...

References

Giri S and Singh AK. (2014). Assessment of surface water quality using heavy metal pollution index in Subarnarekha River, India. Water Quality, Exposure and Health, 5(4), 173-182.

Murphy BR and Whitehead SS. (2011). Immune response to dengue virus and prospects for a vaccine. Annual review of immunology, 29, 587-619.

Gubler DJ. (2006). Dengue/dengue haemorrhagic fever: history and current status. In New Treatment Strategies for Dengue and Other Flaviviral Diseases: Novartis Foundation Symposium, 277, 3-22.

World Health Organization, Special Programme for Research, Training in Tropical Diseases, World Health Organization. Department of Control of Neglected Tropical Diseases, World Health Organization. Epidemic, & Pandemic Alert. (2009). Dengue: guidelines for diagnosis, treatment, prevention and control. World Health Organization.

Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL and Myers MF. (2013). The global distribution and burden of dengue. Nature, 496(7446), 504.

Malavige GN, Fernando S, Fernando DJ and Seneviratne SL. (2004). Dengue viral infections. Postgraduate medical journal, 80(948), 588-601.

Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng, LE, Brady OJ and Chuang TW. (2016). The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. The Lancet infectious diseases, 16(6), 712-723.

World Health Organization, Special Programme for Research, Training in Tropical Diseases, World Health Organization. Department of Control of Neglected Tropical Diseases, World Health Organization. Epidemic, & Pandemic Alert. (2009). Dengue: guidelines for diagnosis, treatment, prevention and control. World Health Organization.

Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL and Myers MF. (2013). The global distribution and burden of dengue. Nature, 496(7446), 504.

Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG and Hay SI. (2012). Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS neglected tropical diseases, 6(8), e1760.

Malavige GN, Fernando S, Fernando DJ and Seneviratne SL. (2004). Dengue viral infections. Postgraduate medical journal, 80(948), 588-601.

Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ and Chuang T.W. (2016). The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. The Lancet infectious diseases, 16(6), 712-723.

Ackermann M and Padmanabhan R. (2001). De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase. Journal of Biological Chemistry, 276(43), 39926-39937.

Modis Y, Ogata S, Clements D and Harrison SC. (2005). Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. Journal of virology, 79(2), 1223-1231.

Swaminathan S and Khanna N. (2013). Experimental dengue vaccines. In Molecular Vaccines, 135-151, Springer, Vienna.

Barniol J, Gaczkowski R, Barbato EV da Cunha RV, Salgado D, Martínez E and Lum, LC. (2011). Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries. BMC infectious diseases, 11(1), 106.

Narvaez F, Gutierrez G, Pérez MA, Elizondo D, Nuñez A, Balmaseda A and Harris E. (2011). Evaluation of the traditional and revised WHO classifications of Dengue disease severity. PLoS neglected tropical diseases, 5(11), e1397.

De Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM and De Silva AM. (2012). Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proceedings of the National Academy of Sciences, 109(19), 7439-7444.

Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M and Monath TP. (2000). Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. Journal of virology, 74(12), 5477-5485.

Guy B, Saville M and Lang J. (2010). Development of Sanofi Pasteur tetravalent dengue vaccine. Human vaccines, 6(9), 696-705.

Osorio JE, Brewoo JN, Silengo SJ, Arguello J, Moldovan IR, Tary-Lehmann M and Stinchcomb DT. (2011). Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. The American journal of tropical medicine and hygiene, 84(6), 978-987.

Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A, Haller AA and Luy BE. (2014). Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. The Lancet Infectious Diseases, 14(9), 830-838.

Khetarpal N and Khanna I. (2016). Dengue fever: causes, complications, and vaccine strategies. Journal of immunology research, 2016.

Simmons M, Murphy GS and Hayes CG. (2001). Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. The American journal of tropical medicine and hygiene, 65(2), 159-161.

Hermida L, Rodríguez R, Lazo L, Bernardo L, Silva R, Zulueta A and Guillén G. (2004). A fragment of the envelope protein from dengue‐1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnology and applied biochemistry, 39(1), 107-114.

Hermida L, Rodrıguez R, Lazo, L, Silva, R, Zulueta, A, Chinea, G and Guillén G. (2004). A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. Journal of virological methods, 115(1), 41-49.

Hermida L, BernardonL, Martín J, Alvarez M, Prado I, López C and Pérez AB. (2006). A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine, 24(16), 3165-3171.

Danko JR, Beckett CG and Porter KR. (2011). Development of dengue DNA vaccines. Vaccine, 29(42), 7261-7266.

Beckett CG, Tjaden J, Burgess T, Danko JR, Tamminga C, Simmons M and Hayes CG. (2011). Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine, 29(5), 960-968.

Porter KR, Ewing D, Chen L, Wu SJ, Hayes CG, Ferrari M and Raviprakash K. (2012). Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine. Vaccine, 30(2), 336-341.

Raviprakash K, Luke T, Doukas J, Danko J, Porter K, Burgess T and Kochel T. (2012). A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits. Human vaccines & immunotherapeutics, 8(12), 1764-1768.

Khetarpal N, and Khanna I. (2016). Dengue fever: causes, complications, and vaccine strategies. Journal of immunology research, 2016.

Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm J and Porter K. (2008). A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. Journal of virology, 82(14), 6927-6934.

White LJ, Parsons MM, Whitmore AC, Williams BM, De Silva A and Johnston RE. (2007). An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. Journal of virology, 81(19), 10329-10339.

Brandler S, Lucas-Hourani M, Moris A, Frenkiel MP, Combredet C, Février M and Tangy F. (2007). Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS neglected tropical diseases, 1(3), e96.

Holman DH, Wang D, Raviprakash K, Raja NU, Luo M, Zhang J and Dong JY. (2007). Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clinical and Vaccine Immunology, 14(2), 182-189.

Raja NU, Holman DH., Wang D, Raviprakash, K, Juompan, LY, Deitz, SB and Dong JY. (2007). Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector. The American journal of tropical medicine and hygiene, 76(4), 743-751.

Suzuki R, Winkelmann, ER. and Mason PW. (2009). Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2. Journal of virology, 83(4), 1870-1880.

Mani S, Tripathi L, Raut R, Tyagi P, Arora U, Barman T and Swaminathan S. (2013). Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies. PLoS One, 8(5), e64595.

Swaminathan S and Khanna N. (2013). Experimental dengue vaccines. In Molecular Vaccines (pp. 135-151). Springer, Vienna.